Question: NR has ductal carcinoma in situ (ER+, PR+, HER2-). Most appropriate treatment recommendation?

Answer Choices:\n\nA. Surgery then raloxifene B. Surgery then doxorubicin C. Surgery then radiation D. Surgery then tamoxifen

Answer:\nD

 

Question: Which statement best describes evidence/recommendations for calcium & vitamin D in fracture prevention?

Answer Choices:\n\nA. 1400 mg Ca/day & 4000 IU vit D/day is the goal B. Proven to reduce fractures, with no CV risk C. Prefer dietary calcium; ensure sufficient vit D D. Recommended for all postmenopausal women

Answer:\nC

 

Question: The primary mechanism of anthracycline (e.g. doxorubicin) cytotoxicity is:

Answer Choices:\n\nA. Prevention of HER2 receptor dimerization B. Initiation of CD8 T cell killing C. Inhibition of microtubule disassembly D. Intercalation into DNA & inhibition of topoisomerase II

Answer:\nD

 

Question: Which agent is preferred in women on tamoxifen because it is NOT a strong CYP2D6 inhibitor?

Answer Choices:\n\nA. Fluoxetine B. Paroxetine C. Bupropion D. Citalopram

Answer:\nD

 

Question: KJ is 62, T-score –2.7 (femoral neck). Most appropriate recommendation?

Answer Choices:\n\nA. Raloxifene (Evista®) B. Abaloparatide (Tymlos®) C. Alendronate (Fosamax®) D. Romosozumab (Evenity®)

Answer:\nC

 

Question: Which medication is approved for prevention, but not treatment, of postmenopausal osteoporosis?

Answer Choices:\n\nA. Conjugated estrogens/bazedoxifene (Duavee®) B. Teriparatide (Forteo®) C. Alendronate (Fosamax®) D. Raloxifene (Evista®)

Answer:\nA

 

Question: Which represent(s) an indication for hormone therapy in a peri/postmenopausal woman? (Select ALL)

Answer Choices:\n\nA. Frequent hot flushes affecting QoL/sleep B. Prevention of endometrial cancer C. Frequent hot flushes not impacting daily functioning D. Prevention of postmenopausal osteoporosis

Answer:\nA and D

 

Question: Most appropriate safe & effective recommendation for a postmenopausal woman with vaginal dryness (uterus intact)?

Answer Choices:\n\nA. Brisdelle® (paroxetine) B. Systemic estrogen therapy C. Low-dose vaginal/local estrogen D. Systemic estrogen + progestin

Answer:\nC

 

Question: Bisphosphonates exert their therapeutic effects in osteoporosis by:

Answer Choices:\n\nA. Increasing osteoblast activity B. Increasing calcium absorption in the gut C. Decreasing osteoclast activity D. Decreasing renal calcium excretion

Answer:\nC

 

Question: Which recommendation (diet/supplements/lifestyle) is most important for women of reproductive age?

Answer Choices:\n\nA. Avoid fish entirely B. Smoking cessation beneficial at all stages C. Wait to start folic acid until pregnancy is confirmed D. Light alcohol is definitively safe

Answer:\nB

 

Question: The figure shows inhibition of osteoclast differentiation and promotes osteoclast apoptosis. Which osteoporosis medication matches this mechanism?

Answer Choices:\n\nA. Teriparatide (Forteo®) B. Romosozumab (Evenity®) C. Denosumab (Prolia®) D. Alendronate (Fosamax®)

Answer:\nC

 

Question: Which is most likely to occur in a woman with osteoporosis?

Answer Choices:\n\nA. Hip fracture without alendronate B. Atypical femur fracture with zoledronic acid C. Osteonecrosis of jaw with ibandronate D. Flu-like symptoms with risedronate

Answer:\nA

 

Question: During the ______ phase, the major source of high levels of progesterone is the ______.

Answer Choices:\n\nA. Follicular; corpus luteum B. Luteal; corpus luteum C. Follicular; developing follicle D. Luteal; developing follicle

Answer:\nB

 

Question: Increased osteoclast activity is associated with which form(s) of osteoporosis? (Select ALL)

Answer Choices:\n\nA. Glucocorticoid-induced B. Senile C. Postmenopausal

Answer:\nA and C

 

Question: Which layer of the uterine wall is fed by coiled (spiral) arteries?

Answer Choices:\n\nA. Stratum functionalis B. Stratum basalis C. Myometrium D. Peritoneum

Answer:\nA

 

Question: Release of IL‑1 and IL‑6 leads to:

Answer Choices:\n\nA. ↑ osteoblast, ↓ osteoclast B. ↓ osteoblast, ↓ osteoclast C. ↓ osteoblast, ↑ osteoclast D. ↑ osteoblast, ↑ osteoclast

Answer:\nC

 

Question: During which ovarian phase does the corpus luteum die, causing estrogen & progesterone to sharply decline?

Answer Choices:\n\nA. Follicular phase B. Proliferative phase C. Luteal phase D. Menses

Answer:\nC